[
    [
        {
            "time": "",
            "original_text": "新股消息 | 贝达药业递表港交所主板，其收入依赖靶向抗癌创新药埃克替尼",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "主板",
                    "靶向抗癌",
                    "埃克替尼"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新股消息 | 贝达药业递表港交所主板，其收入依赖靶向抗癌创新药埃克替尼",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：已向香港联交所重新递交上市申请并刊发申请版本资料集",
            "features": {
                "keywords": [
                    "贝达药业",
                    "香港联交所",
                    "上市申请",
                    "资料集"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：已向香港联交所重新递交上市申请并刊发申请版本资料集",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：股东凯铭投资累计质押3431万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯铭投资",
                    "质押",
                    "股份"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)股东凯铭投资累计质押3431万股",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)股东凯铭投资解除质押350万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯铭投资",
                    "解除质押",
                    "股份"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)股东凯铭投资解除质押350万股",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业向港交所提交上市申请书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "上市申请书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业向港交所提交上市申请书",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "核心产品或有知识产权纠纷 益方生物科创板IPO能否顺利推进？高瓴等明星资本已下注",
            "features": {
                "keywords": [
                    "贝达药业",
                    "益方生物",
                    "知识产权纠纷",
                    "科创板",
                    "IPO",
                    "高瓴资本"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "核心产品或有知识产权纠纷 益方生物科创板IPO能否顺利推进？高瓴等明星资本已下注",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "云顶新冠疫苗新动作，又一贝伐珠单抗生物类似药获批",
            "features": {
                "keywords": [
                    "云顶",
                    "新冠疫苗",
                    "贝伐珠单抗",
                    "生物类似药",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "云顶新冠疫苗新动作，又一贝伐珠单抗生物类似药获批",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "「国内外药企研发进展」国内首个BCR-ABL 抑制剂获批上市；恒瑞医药2项临床试验申请获批准······",
            "features": {
                "keywords": [
                    "药企研发",
                    "BCR-ABL 抑制剂",
                    "恒瑞医药",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "「国内外药企研发进展」国内首个BCR-ABL 抑制剂获批上市；恒瑞医药2项临床试验申请获批准······",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]